Emergent Biosolutions Inc   (EBS)
Other Ticker:  
Price: $3.3900 $0.16 4.954%
Day's High: $3.57 Week Perf: 18.95 %
Day's Low: $ 3.21 30 Day Perf: 102.99 %
Volume (M): 2,258 52 Wk High: $ 13.67
Volume (M$): $ 7,655 52 Wk Avg: $5.38
Open: $3.25 52 Wk Low: $1.42

 Market Capitalization (Millions $) 176
 Shares Outstanding (Millions) 52
 Employees 2,100
 Revenues (TTM) (Millions $) 1,101
 Net Income (TTM) (Millions $) -784
 Cash Flow (TTM) (Millions $) -153
 Capital Exp. (TTM) (Millions $) 86

Emergent Biosolutions Inc
Emergent BioSolutions Inc. is a publicly traded biotechnology company headquartered in Gaithersburg, Maryland, USA. The company specializes in the development, manufacturing, and commercialization of vaccines and immunotherapies for infectious diseases and biodefense.

Founded in 1998, Emergent BioSolutions has grown to become a leading provider of medical countermeasures to governments, militaries, and private organizations around the world. The company's portfolio of products includes vaccines for anthrax, smallpox, and typhoid fever, as well as treatments for botulism and nerve agents.

Emergent BioSolutions operates a state-of-the-art manufacturing facility in Baltimore, Maryland, which has the capacity to produce millions of vaccine doses per year. The facility is equipped with advanced technologies and processes to ensure the highest levels of quality and safety.

The company has a strong focus on research and development, with dedicated teams working on the discovery and development of new vaccines and therapies. Emergent BioSolutions also partners with leading academic and research institutions to accelerate the development of breakthrough treatments.

In addition to its biodefense work, Emergent BioSolutions is actively involved in developing treatments for infectious diseases such as COVID-19. The company has partnered with other biotech firms and government agencies to develop potential treatments and vaccines for the virus.

Overall, Emergent BioSolutions Inc. is a dynamic and innovative biotech company that is dedicated to improving public health and safety through the development and manufacturing of life-saving vaccines and therapies.

   Company Address: 400 Professional Drive, Suite 400 Gaithersburg, 20879 MD
   Company Phone Number: 631-3200   Stock Exchange / Ticker: NYSE EBS
   EBS is expected to report next financial results on March 06, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Emergent BioSolutions Bags $235.8 Million Contract to Supply Anthrax Vaccine to U.S. Military

Published Thu, Jan 11 2024 1:01 PM UTC

Emergent BioSolutions Inc, a Maryland-based life sciences company, announced it has been awarded an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract, which has a maximum value of $235.8 million. The contract requires the company to supply its BioThrax Anthrax Vaccine Adsorbed to all branches of the U.S. military. BioThrax is the only anthrax vaccine licen...

Emergent Biosolutions Inc

Emergent BioSolutions Reports Surge in Revenue for Q3 2023, Despite Continuing Profitability Challenges

Emergent BioSolutions Inc. (EBS), a leading company in the Major Pharmaceutical Preparations industry, has reported some interesting financial results for the third quarter of 2023. While many of its industry counterparts have experienced declines in revenue, EBS has shown a significant surge in revenue, increasing by 12.708% from the previous year to $270.50 million.
However, it is worth noting that despite the revenue increase, EBS has also seen an extension of losses, with a shortfall of $-5.08 per share. This is an improvement from the previous year when the company reported a loss of $-5.15 per share. For the fiscal interval ending September 30, 2023, EBS realized a net shortfall of $-263.400 million, which is higher than the $-75.700 million from the same period last year.

Product Service News

Emergent BioSolutions Secures $75 Million Contract Option and Achieves Steady Revenue Growth

Published Tue, Nov 28 2023 11:59 AM UTC

In a significant boost to Emergent BioSolutions Inc. (NYSE: EBS), the Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a contract option worth $75 million. This contract aims to procure doses of CYFENDUS, the newly licensed anthrax vaccine for the United States Department of Health and Human Services. The company expects to com...

Emergent Biosolutions Inc

Emergent Biosolutions Inc. Dominates Major Pharmaceutical Preparations Industry with Skyrocketing Revenue Amidst Share Shortfall and Stock Decline

Financial News Report: Emergent Biosolutions Inc. Reports Increase in Revenue, Share Shortfall, and Declining Stock Performance
Emergent Biosolutions Inc. recently released its financial results for the most recent fiscal period, revealing a significant increase in revenue. However, the company also reported a shortfall per share. This news comes amid overall growth in the major pharmaceutical preparations industry during the second quarter of 2023.
According to the report, Emergent Biosolutions Inc. experienced a surge in revenue, reaching $337.90 million, representing a 39.225% increase from the same reporting period the previous year. This growth is higher compared to other major pharmaceutical preparations industry contemporaries, which only saw a 2.65% rise in business during the second quarter of 2023 when compared to Q2 of 2022.

Emergent Biosolutions Inc

Emergent Biosolutions Inc in Dire Straits: A Bitter Plunge in Top-line Figures Marks a Perilous Fiscal Year

Emergent Biosolutions Inc: A Company in Crisis
Emergent Biosolutions Inc, a global life sciences company, released dismal financial results for the fiscal year ending March 31, 2023. The company posted a massive loss of $-3.65 per share, which is a significant decline from the $-0.07 loss per share from the previous fiscal year. The losses have been piling up for Emergent Biosolutions Inc, as they are unable to keep up with their expenses and generate revenue to cover their costs.
According to the financial report, the revenue of the company has dropped by an alarming rate of -46.309%. The revenue for the fiscal year ending March 31, 2023, was $165.10 million, which is considerably lower than the $307.50 million from the previous year. The decrease in revenue is a massive blow to the company, as they are struggling to maintain a steady inflow of funds to keep their operations afloat.


Emergent Biosolutions Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com